SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Theander E, Jacobsson LT. Relationship of Sjögren's syndrome to other connective tissue and autoimmune disorders. Rheum Dis Clin North Am 2008; 34: 93547.
  • 2
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 3
    Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 256981.
  • 4
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, for the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 5548.
  • 5
    Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Firestein GS, Budd RC, Harris ED Jr, McInnes IB, Ruddy S, Sergent JS, editors. Kelley's textbook of rheumatology. 8th ed. Philadelphia: Elsevier; 2008. p. 10989.
  • 6
    Fauchais AL, Martel C, Gondran G, Lambert M, Launay D, Jauberteau M. Immunological profile in primary Sjogren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmunity Rev 2010; 9: 5959.
  • 7
    Goldberg J, Pinals RS. Felty syndrome. Semin Arthritis Rheum 1980; 10: 5265.
  • 8
    Barton JC, Prasthofer EF, Egan ML, Heck LW Jr, Koopman WJ, Grossi CE. Rheumatoid arthritis associated with expanded populations of granular lymphocytes. Ann Intern Med 1986; 104: 31423.
  • 9
    Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992; 19: 42430.
  • 10
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 11
    Kucukardali Y, Solmazgul E, Kunter E, Oncul O, Yildirim S, Kaplan M. Kikuchi-Fujimoto disease: analysis of 244 cases. Clin Rheumatol 2007; 26: 504.
  • 12
    Menard O, Petit N, Gillet P, Gaucher A, Martinet Y. Association of histologically proven rheumatoid arthritis with pulmonary sarcoidosis. Eur Respir J 1995; 8: 4723.
  • 13
    Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68: 13105.
  • 14
    Dahlgren M, Khosroshahi A, Nielsen GP, Deshpande V, Stone JH. Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken) 2010; 62: 13128.
  • 15
    Huang TY, Wu TS, Yang CC, Chiang PC, Yu KH, Lee MH. Tuberculous arthritis: a fourteen-year experience at a tertiary teaching hospital in Taiwan. J Microbiol Immunol Infect 2007; 40: 4939.
  • 16
    Vassilopoulos D, Manolakopoulos S. Rheumatic manifestations of hepatitis. Curr Opin Rheumatol 2010; 22: 916.
  • 17
    Reveille JD, Williams FM. Infection and musculoskeletal conditions: rheumatologic complications of HIV infection. Best Pract Res Clin Rheumatol 2006; 20: 115979.
  • 18
    Clark EG, Danbolt N. The Oslo study of the natural course of untreated syphilis: an epidemiologic investigation based on a re-study of the Boeck-Bruusgaard material. J Chronic Dis 1955; 2: 31144.
  • 19
    Davis PG, Fordham JN. Arthritis and angioimmunoblastic lymphadenopathy. Ann Rheum Dis 1983; 42: 5168.
  • 20
    Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692701.
  • 21
    Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol 2008; 27: 5113.
  • 22
    Brennan MT, Pillemer SR, Goldbach-Mansky R, El-Gabalawy H, Schumacher HR Jr, Fox PC. Focal sialadenitis in patients with early synovitis. Clin Exp Rheumatol 2001; 19: 4446.
  • 23
    Kauppi M, Pukkala E, Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997; 8: 2014.
  • 24
    Tokuyasu H, Harada T, Touge H, Kawasaki Y, Maeda R, Isowa N, et al. Primary Sjögren's syndrome complicated by sarcoidosis. Intern Med 2008; 47: 204952.
  • 25
    Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor α therapy: a new “class effect” paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum 2010; 39: 3139.
  • 26
    Wollina U. Pyoderma gangrenosum: a review. Orphanet J Rare Dis 2007; 2: 1926.
  • 27
    Hayes RC, Curtis A. Pyoderma gangrenosum with a contiguous erosion of the distal ulna. J Cutan Med Surg 2004; 8: 1625.
  • 28
    Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum: a review of 86 patients. Q J Med 1985; 55: 17386.
  • 29
    Charles CA, Bialy TL, Falabella AF, Eaglstein WH, Kerdel FA, Kirsner RS. Poor prognosis of arthritis-associated pyoderma gangrenosum. Arch Dermatol 2004; 140: 8614.
  • 30
    Pacifico F, Di Giacomo A, Vergineo PP. Pyoderma gangrenosum and rheumatoid arthritis with massive necrotic ulcer of the right foot. Wounds 2009; 21: 3741.
  • 31
    Teite AD. Treatment of pyoderma gangrenosum with methotrexate. Cutis 1996; 57: 3268.
  • 32
    Kramer N, Berman EL, Rosenstein ED. Pyoderma gangrenosum complicating Felty's syndrome. J Rheumatol 1990; 17: 107982.
  • 33
    Bhat RM, Shetty SS, Kamath GH. Pyoderma gangrenosum in childhood. Int J Dermatol 2004; 43: 2057.
  • 34
    Curioni S, D'Amico M, Quartagno R, Martino S, Dell'Antonio G, Cusi D. Castleman's disease with nephritic syndrome, amyloidosis and autoimmune manifestations. Nephrol Dial Transplant 2001; 16: 14758.
  • 35
    Duguid CM, O'Loughlin S, Otridge B, Powell FC. Paraneoplastic pyoderma gangrenosum. Australas J Dermatol 1993; 34: 1722.
  • 36
    Vandevyvere K, Luyten FP, Verschueren P, Lories R, Segaert S, Westhovens R. Pyoderma gangrenosum developing during therapy with TNF-α antagonists in a patient with rheumatoid arthritis [letter]. Clin Rheumatol 2007; 26: 22056.
  • 37
    Disla E, Quayum B, Cuppari GG, Pancorbo, R. Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. J Clin Rheumatol 2004; 10: 502.
  • 38
    Van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 2010; 8: 48698.
  • 39
    Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol 2004; 43: 698704.
  • 40
    Oksenhendler E, Boulanger E, Galicier L, Du MQ, Dupin N, Diss TC, et al. High incidence of Kaposi sarcoma associated herpes virus related non Hodgkin lymphoma in patients with HIV infection and multicentric Castleman's disease. Blood 2002; 99: 23316.
  • 41
    Bianchi MM, Narvaez J, Santo P, Rios-Rodriguez V, de la Fuente D, Roig-Vilaseca D, et al. Multicentric Castleman's disease mimicking adult-onset Still's disease. Joint Bone Spine 2009; 76: 3047.
  • 42
    Nishimoto N. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol 2005; 28: 22130.
  • 43
    Jacobs SA, Vidnovic N, Patel H, Soma LA, Chang Y, Bass N, et al. Durable remission of HIV-negative, Kaposi's sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate. Clin Rheumatol 2007; 26: 114850.
  • 44
    Ben-Chetrit E, Flusser D, Okon E, Ackerman Z, Rubinow A. Multicentric Castleman's disease associated with rheumatoid arthritis: a possible role of hepatitis B antigen. Ann Rheum Dis 1989; 48: 32630.
  • 45
    Uson J, Balsa A, Pascual-Salcedo D, Cabezas JA, Gonzalez-Tarrio JM, Martin-Mola E, et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 1997; 24: 206975.
  • 46
    Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009; 8: 53842.
  • 47
    Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 17619.
  • 48
    Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106: 262732.
  • 49
    Reddy D, Mitesuyasu R. HIV associated multicentric Castleman disease. Curr Opin Oncol 2011; 23: 47581.
  • 50
    Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330: 6025.
  • 51
    Ide M, Kawachi Y, Izumi Y, Kasagi K, Ogino T. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol 2006; 76: 11923.
  • 52
    Martin F, Chan AC. Pathogenic roles of B cells in human review: insights from the clinic. Immunity 2004; 20: 51727.
  • 53
    Hansen A, Lipsky PE, Dorner T. Immunopathogenesis of primary Sjogren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol 2005; 17: 55865.
  • 54
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793806.
  • 55
    Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo controlled trial. Arthritis Rheum 2010; 62: 9608.
  • 56
    Mitch WE, Goldberg AL. Mechanisms of muscle wasting: the role of the ubiquitin-proteasome pathway. N Engl J Med 1996; 335: 1897905.
  • 57
    Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Rheumatoid cachexia and cardiovascular disease [review]. Nat Rev Rheumatol 2010; 6: 44551.
  • 58
    Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Nevill AM, Douglas KM, Jamurtas A, et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007; 66: 131621.